Imunon (IMNN)
Nasdaq Market Closed
Imunon, Inc. is a clinical-stage biotechnology company focused on DNA-based medicines that use the body’s own cellular machinery to produce therapeutic proteins or immune-stimulating antigens. Rather than relying on viral vectors, the company develops non-viral DNA delivery systems intended to support repeat dosing, targeted administration and scalable manufacturing across multiple disease areas.
The company’s main therapeutic platform is TheraPlas, which is designed to deliver DNA instructions for proteins and cytokines directly to diseased tissue. Its lead clinical candidate, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer. The programme is intended to stimulate an anti-tumour immune response in the tumour environment, with development focused on patients with advanced ovarian cancer in combination with established treatment approaches.
Imunon is also developing PlaCCine, a DNA vaccine platform that encodes viral antigens to trigger protective immune responses. This modality reflects the company’s broader effort to apply non-viral DNA technology beyond oncology, including infectious disease prevention. The platform approach is built around the idea that DNA constructs can be adapted to different targets while using related delivery and formulation capabilities.
As a biotechnology stock, Imunon’s outlook is closely linked to clinical trial execution, safety and efficacy results, regulatory interactions and access to capital for continued development. Its distinguishing feature is the attempt to turn non-viral DNA delivery into a flexible therapeutic and vaccine engine, with IMNN-001 serving as the most advanced test of that strategy in a high-need cancer setting.
Last updated
- Market Cap
- 8.82M
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- 4.03M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 997 LENOX DRIVE, LAWRENCEVILLE, NJ, 08648
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
IMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial
Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101
IMUNON Reports Compliance with Nasdaq Listing Requirements
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
IMUNON Announces Leadership Change
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update
IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023
IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress
IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 8.82M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 4.03M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 2.63
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -0.28
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -3.48
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -15.06M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -435.81%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -182.59%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.59
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.59
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 1.15
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 45.95K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 2.1
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -4.31M | -4.26M | -3.48M | -2.77M | -4.15M |
| EBITDA | -4.24M | -4.19M | -3.4M | -2.69M | -4.08M |
| Net income | -4.25M | -4.22M | -3.43M | -2.74M | -4.1M |
| Basic EPS | -0.84 | -1.3 | -1.16 | -1.87 | -3.15 |
| Diluted EPS | -0.84 | -1.3 | -1.16 | -1.87 | -3.15 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 8.02M | 12.29M | 8.99M | 8.79M | 6.86M |
| Total liabilities | 4.66M | 5.23M | 4.91M | 6.13M | 6.41M |
| Total equity | 3.36M | 7.06M | 4.08M | 2.66M | 452.03K |
| Cash & equivalents | 4.79M | 8.78M | 5.25M | 4.73M | 2.87M |
| Current assets | 6.62M | 10.72M | 7.26M | 6.89M | 5.09M |
| Current liabilities | 4.17M | 4.62M | 4.2M | 5.32M | 5.8M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -3.99M | -3.66M | -4.44M | -2.95M | -2.85M |
| Investing cash flow | — | -3.59K | 0 | -17.33K | -259.65K |
| Financing cash flow | -1.81K | 7.19M | 4.96M | 4.83M | 105.69K |
| Change in cash | -3.99M | 3.53M | 522.15K | 1.86M | -3M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — Imunon, Inc. | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing | |
| form 4 | Form 4 — Lindborg Stacy | View Filing | |
| form 4 | Form 4 — Lindborg Stacy | View Filing | |
| form 4 | Form 4 — Fritz Frederick J. | View Filing | |
| form 4 | Form 4 — Braun Donald P | View Filing | |
| form 4 | Form 4 — Dentzer James E | View Filing | |
| form 4 | Form 4 — Pellizzari Christine A | View Filing | |
| form 4 | Form 4 — Tardugno Michael H | View Filing | |
| form 4 | Form 4 — Tardugno Michael H | View Filing | |
| edgar index | SCHEDULE 13G/A — Imunon, Inc. | View Filing | |
| edgar index | 8-K — Imunon, Inc. | View Filing | |
| edgar index | 10-Q — Imunon, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEF 14A — Imunon, Inc. | View Filing | |
| edgar index | 8-K — Imunon, Inc. | View Filing | |
| edgar index | ARS — Imunon, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B5 — Imunon, Inc. | View Filing | |
| edgar index | 8-K — Imunon, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — Imunon, Inc. | View Filing | |
| edgar index | 8-K — Imunon, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 3 — Imunon, Inc. | View Filing | |
| form 3 | Form 3 — CHURCH JEFFREY WAYNE | View Filing | |
| form 3 | Form 3 — CHURCH JEFFREY WAYNE | View Filing | |
| form 3 | Form 3 — CHURCH JEFFREY WAYNE | View Filing | |
| edgar index | 8-K — Imunon, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing | |
| form 4 | Form 4 — Lindborg Stacy | View Filing | |
| form 4 | Form 4 — Tardugno Michael H | View Filing | |
| form 4 | Form 4 — Dentzer James E | View Filing | |
| form 4 | Form 4 — Braun Donald P | View Filing | |
| form 4 | Form 4 — Pellizzari Christine A | View Filing | |
| form 4 | Form 4 — Eylward Susan | View Filing | |
| form 4 | Form 4 — Faller Douglas Vincent | View Filing | |
| form 4 | Form 4 — Fritz Frederick J. | View Filing | |
| form 4 | Form 4 — Anwer Khursheed | View Filing | |
| form 4 | Form 4 — Bragg Kimberly | View Filing | |
| edgar index | 8-K — Imunon, Inc. | View Filing | |
| edgar index | 424B5 — Imunon, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Imunon, Inc. | View Filing | |
| edgar index | 10-Q — Imunon, Inc. | View Filing | |
| edgar index | S-8 — Imunon, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | UPLOAD — Imunon, Inc. | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing | |
| form 4 | Form 4 — Lindborg Stacy | View Filing | |
| form 4 | Form 4 — Lindborg Stacy | View Filing | |
| form 4 | Form 4 — Lindborg Stacy | View Filing | |
| edgar index | 8-K — Imunon, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | CORRESP — Imunon, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Imunon, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Imunon, Inc. | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing | |
| edgar index | 4 — Imunon, Inc. | View Filing |